Evaluation of Prognostic Factors and Survival Results in Pancreatic Carcinomas in Turkey

被引:8
作者
Canyilmaz, Emine [1 ]
Serdar, Lasif [1 ]
Uslu, Gonca Hanedan [2 ]
Soydemir, Gulsen [1 ]
Bahat, Zumrut [1 ]
Yoney, Adnan [1 ]
机构
[1] Karadeniz Tech Univ, Fac Med, Dept Radiat Oncol, Trabzon, Turkey
[2] Kanuni Res & Educ Hosp, Trabzon, Turkey
关键词
Pancreatic cancer; radiotherapy; chemotherapy; CEA; DUCTAL ADENOCARCINOMA; CURATIVE RESECTION; CANCER; CHEMOTHERAPY; GEMCITABINE; CHEMORADIOTHERAPY; 5-FLUOROURACIL; PATTERNS; THERAPY; FAILURE;
D O I
10.7314/APJCP.2013.14.11.6573
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The goal of this retrospective study was to evaluate patient characteristics, treatment modalitiesand prognostic factors in Turkish patients with pancreatic cancer. Materials and Methods: Between January 1997 and December 2012, 64 patients who presented to the Department of Radiation Oncology, Karadeniz Technical University, Faculty of Medicine with a diagnosis of pancreatic cancer were evaluated. The E/K ratio of the cases was 2.4/1 and the median age was 59.6 (32-80) years, respectively. Some 11 cases (18%) were stage 1, 21 (34.4%) were stage 2, 10 (16.4%) were stage 3, and 19 (31.1%) were metastatic. Results: The mean follow-up time was 15.7 months (0.7-117.5) and loco-regional recurrence was noted in 11 (40.7%) who underwent surgery while metastases were observed in 41 patients (66.1%). The median overall survival (OS) was 11.2 months and the 1, 3 and 5-year OS rates were 41.7%, 9.9% and 7.9% respectively. The median disease-free survival (DFS) was 5.2 month and the1, 2 and 5 year DFS were 22.6%, 7.6% and 3.8% respectively. On univariate analysis, prognostic factors affecting OS included status of the operation (p<0.001), tumor stage (p=0.008), ECOG performance status (p=0.005) and CEA level (p=0.017). On multivariate analysis, prognostic factors affecting survival included status of the operation (p=0.033) and age (p=0.023). Conclusions: In the current study, age and operation status were independent prognostic factors for overall survival with pancreatic patients. Thus, the patients early diagnosis and treatment ars essential. However, prospective studies with more patients are needed for confirmation.
引用
收藏
页码:6573 / 6578
页数:6
相关论文
共 33 条
[11]  
Garcea G, 2008, J PANCREAS, V9, P99
[12]  
GUDJONSSON B, 1995, J AM COLL SURGEONS, V181, P483
[13]   Meta-analysis of randomized trials: Evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer [J].
Heinemann, Volker ;
Boeck, Stefan ;
Hinke, Axel ;
Labianca, Roberto ;
Louvet, Christophe .
BMC CANCER, 2008, 8 (1)
[14]   Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies [J].
Huguet, Florence ;
Andre, Thierry ;
Hammel, Pascal ;
Artru, Pascal ;
Balosso, Jacques ;
Selle, Frederic ;
Deniaud-Alexandre, Elisabeth ;
Ruszniewski, Philippe ;
Touboul, Emmanuel ;
Labianca, Roberto ;
de Gramont, Aimery ;
Louvet, Christophe .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (03) :326-331
[15]   DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic Cancer [J].
Iacobuzio-Donahue, Christine A. ;
Fu, Baojin ;
Yachida, Shinichi ;
Luo, Mingde ;
Abe, Hisashi ;
Henderson, Clark M. ;
Vilardell, Felip ;
Wang, Zheng ;
Keller, Jesse W. ;
Banerjee, Priya ;
Herman, Joseph M. ;
Cameron, John L. ;
Yeo, Charles J. ;
Halushka, Marc K. ;
Eshleman, James R. ;
Raben, Marian ;
Klein, Alison P. ;
Hruban, Ralph H. ;
Hidalgo, Manuel ;
Laheru, Daniel .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (11) :1806-1813
[16]   Prognostic factors in patients with advanced pancreatic cancer treated with systemic chemotherapy [J].
Ishii, H ;
Okada, S ;
Nose, H ;
Yoshimori, M ;
Aoki, K ;
Okusaka, T .
PANCREAS, 1996, 12 (03) :267-271
[17]  
Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI [10.3322/caac.20006, 10.3322/caac.21387]
[18]   Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303) [J].
Kindler, Hedy Lee ;
Niedzwiecki, Donna ;
Hollis, Donna ;
Sutherland, Susan ;
Schrag, Deborah ;
Hurwitz, Herbert ;
Innocenti, Federico ;
Mulcahy, Mary Frances ;
O'Reilly, Eileen ;
Wozniak, Timothy F. ;
Picus, Joel ;
Bhargava, Pankaj ;
Mayer, Robert J. ;
Schilsky, Richard L. ;
Goldberg, Richard M. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (22) :3617-3622
[19]   TREATMENT OF LOCALLY UNRESECTABLE CANCER OF THE STOMACH AND PANCREAS - A RANDOMIZED COMPARISON OF 5-FLUOROURACIL ALONE WITH RADIATION PLUS CONCURRENT AND MAINTENANCE 5-FLUOROURACIL - AN EASTERN-COOPERATIVE-ONCOLOGY-GROUP STUDY [J].
KLAASSEN, DJ ;
MACINTYRE, JM ;
CATTON, GE ;
ENGSTROM, PF ;
MOERTEL, CG .
JOURNAL OF CLINICAL ONCOLOGY, 1985, 3 (03) :373-378
[20]   Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation [J].
Krishnan, Sunil ;
Rana, Vishal ;
Janjan, Nora A. ;
Abbruzzese, James L. ;
Gould, Morris S. ;
Das, Prajnan ;
Delclos, Marc E. ;
Palla, Shana ;
Guha, Sushovan ;
Varadhachary, Gauri ;
Evans, Douglas B. ;
Wolff, Robert A. ;
Crane, Christopher H. .
CANCER, 2006, 107 (11) :2589-2596